Using tiny carriers to improve cancer treatment with specific drugs
Official title: Ultra-Small Epigenetic-Regulating Nanocarrier for Enhanced Synthetic Lethal Therapy
Funded at University of Nebraska Medical Center · NIH-10979025 · Data updated 2026-11-12
This study is looking at a new way to make cancer treatments work better by using a special drug and tiny carriers to deliver it right to tumors, which could help boost the body's immune response and offer new options for people with different types of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | July 9, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $362,741 |
| NIH project number | 1R01CA287091-01A1 |
| Project ID | NIH-10979025 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors, especially those with BRCA mutations or homologous recombination repair deficiencies.
✕Less likely to help
Patients with cancers that are not solid tumors or those who do not have the specific genetic mutations targeted by this therapy may not benefit.
What this research studies
This research focuses on enhancing the effectiveness of cancer therapies by combining a drug called 5-azacytidine with PARP inhibitors, which are particularly effective for certain types of cancer. The approach involves developing ultra-small nanocarriers that can deliver these drugs directly to tumors, improving their bioavailability and therapeutic impact. By targeting tumors more effectively, the research aims to increase the immune response against cancer cells and potentially create new treatment options for patients with various cancer types.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments for patients, particularly those with tumors that are currently difficult to treat.
How similar studies have gone: Other research has shown promising results with similar combination therapies, indicating potential for success in this novel approach.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Sun, Jingjing — University of Nebraska Medical Center
- Study coordinator: Sun, Jingjing
Related research
Other NIH-funded projects on the same topics.
-
Digital malaria surveillance in Ethiopia to improve outbreak detection
A collaboration to add a malaria-specific digital module to an existing surveillance system in Africa to help detect and respond to outbreaks faster.
-
Cross-sector partnership uses digital malaria surveillance in Ethiopia
A US-based team will adapt and test a digital malaria surveillance module in SORMAS to help detect and respond to malaria outbreaks in Ethiopia.
-
Molecular and brain circuits linked to anxiety disorders
A researcher is studying a specific brain circuit to understand what drives anxiety and how it could be treated for people with anxiety disorders.
-
Modulating a brain lipid to reduce injury after newborn brain injury
Aims to test a treatment that changes a brain lipid to lessen damage after a baby’s brain has been deprived of oxygen.
-
Autonomic dysfunction in diabetes and erectile function: brain signals and kidney nerves
A study in diabetic rats explores how brain and kidney nerve signals may contribute to erectile dysfunction in diabetes, with findings that could inform future treatments for men with diabetes who have ED.
-
Multimodal bioelectroceutical approach to bone regeneration in diabetes and aging
A new approach uses electrical signals and tiny drugs inside special scaffolds to help jawbone heal in people with diabetes or aging-related bone problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.